

David J Riese II

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6617778/publications.pdf>

Version: 2024-02-01

50
papers

3,805
citations

236833

25
h-index

206029

48
g-index

53
all docs

53
docs citations

53
times ranked

4346
citing authors

#	ARTICLE	IF	CITATIONS
1	Specificity within the EGF family/ErbB receptor family signaling network. <i>BioEssays</i> , 1998, 20, 41-48.	1.2	695
2	The Cellular Response to Neuregulins Is Governed by Complex Interactions of the erbB Receptor Family. <i>Molecular and Cellular Biology</i> , 1995, 15, 5770-5776.	1.1	364
3	Ligands for ErbB-family receptors encoded by a neuregulin-like gene. <i>Nature</i> , 1997, 387, 509-512.	13.7	272
4	Functional selectivity of EGF family peptide growth factors: Implications for cancer. , 2009, 122, 1-8.		225
5	The Epidermal Growth Factor Receptor Couples Transforming Growth Factor- β , Heparin-binding Epidermal Growth Factor-like Factor, and Amphiregulin to Neu, ErbB-3, and ErbB-4. <i>Journal of Biological Chemistry</i> , 1996, 271, 20047-20052.	1.6	146
6	The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer. <i>Frontiers in Pharmacology</i> , 2020, 11, 574667.	1.6	143
7	Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation. <i>Cancer Research</i> , 2007, 67, 7319-7326.	0.4	136
8	Epiregulin: Roles in normal physiology and cancer. <i>Seminars in Cell and Developmental Biology</i> , 2014, 28, 49-56.	2.3	135
9	Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 263-75.	1.1	129
10	EGFR signaling in breast cancer: Bad to the bone. <i>Seminars in Cell and Developmental Biology</i> , 2010, 21, 951-960.	2.3	129
11	c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. <i>Molecular Cancer Research</i> , 2002, 1, 79-87.	1.5	113
12	Ligand Discrimination in Signaling through an ErbB4 Receptor Homodimer. <i>Journal of Biological Chemistry</i> , 2000, 275, 19803-19807.	1.6	104
13	EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. <i>Growth Factors</i> , 2012, 30, 107-116.	0.5	103
14	Activation of ErbB4 by the Bifunctional Epidermal Growth Factor Family Hormone Epiregulin Is Regulated by ErbB2. <i>Journal of Biological Chemistry</i> , 1998, 273, 11288-11294.	1.6	91
15	Cripto Enhances the Tyrosine Phosphorylation of Shc and Activates Mitogen-activated Protein Kinase (MAPK) in Mammary Epithelial Cells. <i>Journal of Biological Chemistry</i> , 1997, 272, 3330-3335.	1.6	88
16	Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis. <i>BioEssays</i> , 2007, 29, 558-565.	1.2	83
17	Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. <i>Oncogene</i> , 2002, 21, 8442-8452.	2.6	81
18	Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop. <i>Cellular Signalling</i> , 2009, 21, 212-219.	1.7	64

#	ARTICLE	IF	CITATIONS
19	A high throughput, interactive imaging, bright-field wound healing assay. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2011, 79A, 227-232.	1.1	51
20	Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 493-505.	1.1	49
21	Low syndrome patient fibroblasts display Ocr11-specific cell migration defects that cannot be rescued by the homologous Inpp5b phosphatase. <i>Human Molecular Genetics</i> , 2009, 18, 4478-4491.	1.4	49
22	Design, Synthesis, and Biological Evaluation of a Series of Lavendustin A Analogues That Inhibit EGFR and Syk Tyrosine Kinases, as Well as Tubulin Polymerization. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 441-452.	2.9	46
23	A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. <i>Cancer Letters</i> , 2003, 192, 67-74.	3.2	44
24	Modeling oncogene addiction using RNA interference. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 12480-12484.	3.3	41
25	Anilinoalkoxyquinazolines: Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Potential Tumor Imaging Probes. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 7445-7456.	2.9	33
26	ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer. <i>Genes and Cancer</i> , 2011, 2, 792-804.	0.6	33
27	The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein. <i>Pharmacological Reviews</i> , 2022, 74, 18-47.	7.1	31
28	Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase. <i>Oncogene</i> , 2004, 23, 883-893.	2.6	28
29	Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. <i>Experimental Cell Research</i> , 2011, 317, 392-404.	1.2	27
30	Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines. <i>Biochemical and Biophysical Research Communications</i> , 2006, 349, 372-382.	1.0	26
31	Phosphorylation of ErbB4 on Tyrosine 1056 Is Critical for ErbB4 Coupling to Inhibition of Colony Formation by Human Mammary Cell Lines. <i>Oncology Research</i> , 2006, 16, 179-193.	0.6	24
32	Ligand-based receptor tyrosine kinase partial agonists: new paradigm for cancer drug discovery?. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 185-193.	2.5	22
33	Autocrine-Derived Epidermal Growth Factor Receptor Ligands Contribute to Recruitment of Tumor-Associated Macrophage and Growth of Basal Breast Cancer Cells In Vivo. <i>Oncology Research</i> , 2013, 20, 303-317.	0.6	19
34	Reconstitution of Amphiregulin-Epidermal Growth Factor Receptor Signaling in Lung Squamous Cell Carcinomas Activates PTHrP Gene Expression and Contributes to Cancer-Mediated Diseases of the Bone. <i>Molecular Cancer Research</i> , 2009, 7, 1714-1728.	1.5	18
35	Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities. <i>Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research</i> , 2002, 13, 247-56.	0.8	18
36	ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation. <i>Cellular Signalling</i> , 2002, 14, 793-798.	1.7	17

#	ARTICLE	IF	CITATIONS
37	The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2 ¹² and agonist-independent coupling with downstream signalling events. <i>Biochemical Journal</i> , 2006, 396, 79-88.	1.7	16
38	Inter-conversion of neuregulin2 full and partial agonists for ErbB4. <i>Biochemical and Biophysical Research Communications</i> , 2007, 364, 351-357.	1.0	15
39	Comparison of the enantiomers of (±)-doxanthrine, a high efficacy full dopamine D1 receptor agonist, and a reversal of enantioselectivity at D1 versus alpha2C adrenergic receptors. <i>European Neuropsychopharmacology</i> , 2009, 19, 138-146.	0.3	14
40	At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone. <i>Odontology / the Society of the Nippon Dental University</i> , 2012, 100, 109-129.	0.9	14
41	Estrogen receptor ^{1±} , progesterone receptor, and c-erbB/HER-family receptor mRNA detection and phenotype analysis in spontaneous canine models of breast cancer. <i>Journal of Veterinary Science</i> , 2017, 18, 149.	0.5	14
42	EGFR may couple moderate alcohol consumption to increased breast cancer risk. <i>Breast Cancer: Targets and Therapy</i> , 2009, 1, 31.	1.0	13
43	secErbB4-26/549 Antagonizes Ligand-Induced ErbB4 Tyrosine Phosphorylation. <i>Oncology Research</i> , 2004, 14, 589-602.	0.6	13
44	Phe45 of NRG2 ¹² is critical for the affinity of NRG2 ¹² for ErbB4 and for potent stimulation of ErbB4 signaling by NRG2 ¹² . <i>Growth Factors</i> , 2005, 23, 273-283.	0.5	8
45	The Q43L mutant of neuregulin 2 ¹² is a pan-ErbB receptor antagonist. <i>Biochemical Journal</i> , 2012, 443, 133-144.	1.7	7
46	The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056. <i>Growth Factors</i> , 2007, 25, 329-333.	0.5	4
47	Expression and purification of HER2 extracellular domain proteins in Schneider2 insect cells. <i>Protein Expression and Purification</i> , 2016, 125, 26-33.	0.6	3
48	Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics. <i>PLoS ONE</i> , 2020, 15, e0243901.	1.1	3
49	Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant. <i>Journal of Cancer Research and Therapeutic Oncology</i> , 2013, 1, 10.	0.0	3
50	Abstract 814: Identification of ERBB4 mutant alleles that function as tumor drivers. , 2021, , .		0